Jim Cramer weighs the market impact of Eli Lilly and Novo Nordisk's weight loss drugs
'Mad Money' host Jim Cramer compares the weight loss drug offerings from Novo Nordisk and Eli Lilly and talks what investors need to know about both companies.
Видео Jim Cramer weighs the market impact of Eli Lilly and Novo Nordisk's weight loss drugs канала CNBC Television
Видео Jim Cramer weighs the market impact of Eli Lilly and Novo Nordisk's weight loss drugs канала CNBC Television
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Veterans: Next battle
Lightning Round: Vertiv is 'hitting it out of the park', says Jim Cramer
Jim Cramer explains why he favors Eli Lilly in the weight loss drug space
Jim Cramer covers the market's 'Wall of Worry'
The bond market might be the most ferocious brick in the Wall of Worry, says Jim Cramer
How Novo Nordisk's ‘select’ study results could shake up the obesity drug space
Chart Master: What's next for Walmart and Target
Options Action: Traders feeling bullish toward Lucid
Investors should stay in the markets but err on the side of defensiveness, says Adam Hetts
The Fed will continue to overtighten, says Charles Schwab's Kevin Gordon
Biden and Xi's upcoming meeting is about 'setting a tone', says Blueshirt's Gary Dvorchak
Nvidia is a must own in the AI race, says Bernstein's Stacy Rasgon
No reason the S&P 500 can't continue to rally through end of the year, says Solus' Dan Greenhaus
Legendary value investor launches ETF… but it's not a value fund
ETF SIZZLE FOR SOCIAL
Home builders are in a secular run, says Strategas' Chris Verrone
Cantor's Eric Johnston on economy: Outlook is deteriorating
LIVE: White House press secretary Karine Jean-Pierre holds a briefing with reporters — 11/13/23
Camping goes electric
FTX sues crypto exchange Bybit over 2022 withdrawals: CNBC Crypto World